Pixantrone maleate - Topoisomerase II inhibitor DNA intercalating agent oncolytic

被引:2
|
作者
Lolli, Francesco
Tredici, Giovanni
Cavaletti, Guido
机构
[1] Univ Florence, Dipartimento Sci Neurol & Psichiat, I-50127 Florence, Italy
[2] Univ Milano Bicocca, Dipartimento Neurosci & Tecnol Biomed, I-20052 Monza, Italy
关键词
D O I
10.1358/dof.2007.032.08.1123409
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pixantrone is a noncardiotoxic aza-anthracenedione antineoplastic agent related to mitoxantrone. They share the same cytotoxic mechanism of action, interacting with DNA as intercalating agents via inhibition of topoisomerase II. The efficacy of pixantrone as an antineoplastic drug has been demonstrated in phase II/III clinical studies. Pixantrone is also extremely interesting as a putative immunosuppressant; at equiactive doses it is less cardiotoxic than mitoxantrone and it shows similar in vitro and in vivo immunological effects.
引用
收藏
页码:703 / 706
页数:4
相关论文
共 50 条
  • [1] VORELOXIN DNA-Intercalating Drug Topoisomerase II Inhibitor Oncolytic
    Moualla, H.
    Mills, D. A.
    Hromas, R.
    Verschraegen, C. F.
    DRUGS OF THE FUTURE, 2009, 34 (05) : 363 - 374
  • [2] Gimatecan.: DNA-intercalating drug, DNA topoisomerase I inhibitor, Oncolytic
    Sorbera, L. A.
    Serradell, N.
    Bolos, J.
    Rosa, E.
    Bozzo, J.
    DRUGS OF THE FUTURE, 2007, 32 (10) : 859 - 867
  • [3] Lunacridine from Lunasia amara is a DNA intercalating topoisomerase II inhibitor
    Prescotta, Thomas A. K.
    Sadler, Ian H.
    Kiapranis, Robert
    Maciver, Sutherland K.
    JOURNAL OF ETHNOPHARMACOLOGY, 2007, 109 (02) : 289 - 294
  • [4] Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform
    Hasinoff, Brian B.
    Wu, Xing
    Patel, Daywin
    Kanagasabai, Ragu
    Karmahapatra, Soumendrakrishna
    Yalowich, Jack C.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2016, 356 (02): : 397 - 409
  • [5] ETIRINOTECAN PEGOL DNA Topoisomerase 1 Inhibitor Oncolytic
    Nagpal, S.
    Recht, L. D.
    DRUGS OF THE FUTURE, 2013, 38 (04) : 227 - 233
  • [6] CKD-602. Oncolytic, DNA topoisomerase I inhibitor
    Ahn, SK
    Kim, JK
    Hong, CI
    DRUGS OF THE FUTURE, 2000, 25 (12) : 1243 - 1246
  • [7] 9-Aminocamptothecian -: Oncolytic DNA topoisomerase I inhibitor
    不详
    DRUGS OF THE FUTURE, 2000, 25 (09) : 959 - 961
  • [8] Targeting topoisomerase II with the chiral DNA-intercalating ruthenium(II) polypyridyl complexes
    Gao, Feng
    Chao, Hui
    Wang, Jin-Quan
    Yuan, Yi-Xian
    Sun, Bin
    Wei, Yuan-Fang
    Peng, Bin
    Ji, Liang-Nian
    JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2007, 12 (07): : 1015 - 1027
  • [9] Targeting topoisomerase II with the chiral DNA-intercalating ruthenium(II) polypyridyl complexes
    Feng Gao
    Hui Chao
    Jin-Quan Wang
    Yi-Xian Yuan
    Bin Sun
    Yuan-Fang Wei
    Bin Peng
    Liang-Nian Ji
    JBIC Journal of Biological Inorganic Chemistry, 2007, 12 : 1015 - 1027
  • [10] Initial Testing (Stage 1) of the Topoisomerase II Inhibitor Pixantrone, by the Pediatric Preclinical Testing Program
    Kurmasheva, Raushan T.
    Reynolds, C. Patrick
    Kang, Min H.
    Allievi, Cecilia
    Houghton, Peter J.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (05) : 922 - 924